AI-driven autonomous labs for scientific discovery
Lila Sciences, incubated by Flagship Pioneering, is building 'scientific superintelligence' — AI models coupled to autonomous laboratories that run experiments across life and materials science.
Biotech📍 Cambridge, MAFounded 2023
Current Valuation
Private
PRIVATE
QL Price
$8.5B
0% vs last round
QuantLogix's current estimate for Lila Sciences, published 2026-09-21 — in line with the last disclosed round of $8.5B (2026-06).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$8.5B
2026-06
weight 0.81
How this price has held up
No round has priced for Lila Sciences since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-21 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Lila Sciences, 2026-09-21 (997bc2a70649f865).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Lila Sciences going public?
No. Lila Sciences is private and has not filed to go public. There is no S-1 on file.
What is Lila Sciences' valuation in 2026?
No confirmed valuation is on record for Lila Sciences. The roster shows funding and investors where they are public; it does not estimate a mark.
Has Lila Sciences filed an S-1?
No public S-1 is on file for Lila Sciences.
Can you buy Lila Sciences stock?
No. Lila Sciences is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Lila Sciences on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
CEO
Geoffrey von Maltzahn
Founded
2023
HQ
Cambridge, MA
IPO Status
private
Fundraising Status
private
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for Lila Sciences — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-19. Re-checked weekly.
Talent Signal
Hiring trend
▼ Hiring downtrend
-14% vs 2026-08
Open roles
114
via greenhouse
Product-build share
71%
engineering, research, product, design
Trajectory
tightening
heavy product build — 71% of open roles are product-building functions (engineering/research/product) — 37 of 114 open roles are research.
Open roles trending down; no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Associate Engineer/ Engineer I, Formulations and Characterization Associate Scientist/Scientist I, Protein Science DevelopabilityChemistry Technical Program ManagerComputational Scientist I/II, Soft Matter Formulations , Complex FluidsComputational Scientist I/II, Soft Matter Formulations, Solids and MeltsControls Engineer II, Sustaining Engineering
Counted from Lila Sciences's live job board as of 2026-09-14; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.